Kala Bio (KALA) Interest & Investment Income (2016 - 2026)
Kala Bio (KALA) posted Interest & Investment Income of $74000.0 for Q1 2026, down 72.59% sequentially from $270000.0 in Q3 2025, and down 84.02% YoY from $463000.0 in Q1 2025.
Kala Bio (KALA) Interest & Investment Income (2016 - 2026) Analysis & Trends
Kala Bio has reported Interest & Investment Income for 11 years, with the latest figure at $74000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 84.02% year-over-year to $74000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $751000.0 (down 62.73% YoY) and the FY2025 annual result came in at $1.1 million, down 44.55% from the prior year.
- Interest & Investment Income slipped to $74000.0 in Q1 2026 per KALA's latest filing, from $270000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $718000.0 in Q2 2023 and troughed at $8000.0 in Q1 2022.
- A 5-year average of $415312.5 and a median of $470500.0 in 2024 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2026: Interest & Investment Income surged 8337.5% in 2023, then slumped 84.02% in 2026.
- Over 5 years, Interest & Investment Income stood at $354000.0 in 2022, then jumped by 72.32% to $610000.0 in 2023, then retreated by 21.64% to $478000.0 in 2024, then sank by 43.51% to $270000.0 in 2025, then tumbled by 72.59% to $74000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $74000.0, $270000.0, and $407000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | 74,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74,000.00 |
| Sep 30, 2025 | 270,000.00 |
| Jun 30, 2025 | 407,000.00 |
| Mar 31, 2025 | 463,000.00 |
| Dec 31, 2024 | 478,000.00 |
| Sep 30, 2024 | 570,000.00 |
| Jun 30, 2024 | 504,000.00 |
| Mar 31, 2024 | 504,000.00 |
| Dec 31, 2023 | 610,000.00 |
| Sep 30, 2023 | 708,000.00 |
| Jun 30, 2023 | 718,000.00 |
| Mar 31, 2023 | 675,000.00 |
| Dec 31, 2022 | 354,000.00 |
| Sep 30, 2022 | 234,000.00 |
| Jun 30, 2022 | 68,000.00 |
| Mar 31, 2022 | 8,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Sep 30, 2021 | 16,000.00 |
| Jun 30, 2021 | 33,000.00 |
| Mar 31, 2021 | 43,000.00 |